EA201591747A1 - Иммуногенный пептидный конъюгат и способ индуцирования терапевтического гуморального ответа против вируса гриппа с его применением - Google Patents
Иммуногенный пептидный конъюгат и способ индуцирования терапевтического гуморального ответа против вируса гриппа с его применениемInfo
- Publication number
- EA201591747A1 EA201591747A1 EA201591747A EA201591747A EA201591747A1 EA 201591747 A1 EA201591747 A1 EA 201591747A1 EA 201591747 A EA201591747 A EA 201591747A EA 201591747 A EA201591747 A EA 201591747A EA 201591747 A1 EA201591747 A1 EA 201591747A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- influenza
- influenza virus
- peptide conjugates
- response against
- humoral response
- Prior art date
Links
- 239000000863 peptide conjugate Substances 0.000 title abstract 5
- 241000712461 unidentified influenza virus Species 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 230000008348 humoral response Effects 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title 1
- 206010022000 influenza Diseases 0.000 abstract 5
- 101710154606 Hemagglutinin Proteins 0.000 abstract 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 3
- 101710176177 Protein A56 Proteins 0.000 abstract 3
- 230000002163 immunogen Effects 0.000 abstract 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 abstract 2
- 229940098773 bovine serum albumin Drugs 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 239000000185 hemagglutinin Substances 0.000 abstract 1
- 108060003552 hemocyanin Proteins 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000010802 sludge Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Иммуногенные пептидные конъюгаты, полученные из гемагглютинина вируса гриппа, представленные в настоящем описании, индуцируют специфический терапевтический гуморальный ответ против вируса гриппа. Иммуногенные пептидные конъюгаты содержат сегмент из домена области инициации слияния (FIR) белка гемагглютинина вируса гриппа, конъюгированного с белком-носителем, таким как гемоцианин морского блюдца (KLH), бычий сывороточный альбумин (BSA), белок гемагглютинин вируса гриппа (НА) (т.е. полноразмерный НА) и т.п. Иммуногенные пептидные конъюгаты, представленные в настоящем описании, можно применять для лечения или профилактики инфекции гриппа и для получения специфичных к вирусу гриппа терапевтических антител, противодействующих слиянию вируса гриппа и мембраны клетки-хозяина. Пептидные конъюгаты можно составлять в фармацевтических композициях, применимых для лечения широкого спектра или профилактики инфекции гриппа.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/828,988 US9649375B2 (en) | 2013-03-14 | 2013-03-14 | Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith |
PCT/US2014/025968 WO2014160171A2 (en) | 2013-03-14 | 2014-03-13 | Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201591747A1 true EA201591747A1 (ru) | 2016-02-29 |
EA030004B1 EA030004B1 (ru) | 2018-06-29 |
Family
ID=51527967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201591747A EA030004B1 (ru) | 2013-03-14 | 2014-03-13 | Иммуногенный пептидный конъюгат и способ индуцирования терапевтического гуморального ответа против вируса гриппа с его применением |
Country Status (12)
Country | Link |
---|---|
US (3) | US9649375B2 (ru) |
EP (1) | EP2970386A4 (ru) |
JP (1) | JP2016519061A (ru) |
CN (1) | CN105377876A (ru) |
AR (1) | AR095367A1 (ru) |
AU (2) | AU2014244071B2 (ru) |
CA (1) | CA2906519A1 (ru) |
EA (1) | EA030004B1 (ru) |
HK (1) | HK1222184A1 (ru) |
MX (1) | MX2015012399A (ru) |
TW (2) | TW201925238A (ru) |
WO (1) | WO2014160171A2 (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3568157A4 (en) * | 2017-01-13 | 2021-01-06 | National Research Council of Canada | METHOD FOR OPTIMIZING THE PEPTIDE IMMUNO-EPITOP BY GLYCOSYLATION, OPTIMIZED PEPTIDE THEREOF AND ITS USE FOR CONJUGATE VACCINES |
WO2018237010A2 (en) | 2017-06-20 | 2018-12-27 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE |
CN114516907B (zh) * | 2020-11-20 | 2024-03-29 | 中国科学技术大学 | 一种植物抗逆性相关基因atagl70及其编码蛋白与应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2047073A1 (en) | 1990-07-19 | 1992-01-20 | William J. Leanza | Coconjugate vaccines comprising immunogenic protein, hiv related peptides, and anionic moieties |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
US5589174A (en) * | 1992-09-17 | 1996-12-31 | Takara Shuzo Co., Ltd. | Anti-human influenza virus antibody |
US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
EP1034298B1 (en) | 1997-12-05 | 2011-11-02 | The Scripps Research Institute | Humanization of murine antibody |
EP1204425B1 (en) * | 1999-08-19 | 2009-01-07 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
US7189800B2 (en) * | 2001-03-27 | 2007-03-13 | Samuel Bogoch | Replikin peptides in rapid replication of glioma cells and in influenza epidemics |
EP1551453A4 (en) | 2002-06-17 | 2007-04-25 | Us Gov Health & Human Serv | SPECIFICITY GRAFTING OF A MICE RESPONSE TO A HUMAN FRAME |
PT2261377E (pt) * | 2003-11-04 | 2013-11-29 | Univ Tulane | Método para prevenir a fusão vírus:células inibindo a função da região de iniciação de fusão em vírus de rna tendo proteínas do invólucro fusogénicas de membrana de classe |
CA2625406C (en) * | 2005-10-18 | 2016-08-09 | Novavax, Inc. | Functional influenza virus like particles (vlps) |
EP1948227A4 (en) | 2005-10-26 | 2010-03-31 | Protelix Inc | COMBINATORY ANTIGEN VACCINE AGAINST FLU |
US8222204B2 (en) * | 2006-05-03 | 2012-07-17 | The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC | Influenza inhibiting compositions and methods |
BRPI0711229A2 (pt) | 2006-05-31 | 2013-01-08 | Astellas Pharma Inc | anticorpo humanizado da osteopontina anti-humana, polinucleotÍdeo, vetor de expressço, cÉlula hospedeita, mÉtodo para produzir um anticorpo humanizado de osteopontina anti-humana, fÁrmaco terapÊutico, mÉtodo para prevenir ou tratar doenÇa autoimune e uso do anticorpo humanizado de oesteopontina anti-humana |
JP5450402B2 (ja) * | 2007-06-25 | 2014-03-26 | ジ アドミニストレーターズ オブ ザ トゥレーン エデュケーショナル ファンド | インフルエンザを阻害する組成物および方法 |
WO2009111865A1 (en) * | 2008-03-12 | 2009-09-17 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health | Reagents and methods for detecting influenza virus proteins |
JP2012521786A (ja) | 2009-03-30 | 2012-09-20 | モウント シナイ スクール オフ メディシネ | インフルエンザウイルスワクチン及びその使用 |
CA2760392C (en) | 2009-04-29 | 2020-07-28 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Influenza viral peptides and fusion protein for immunization, methods and uses thereof |
WO2010124393A1 (en) | 2009-04-30 | 2010-11-04 | National Research Council Of Canada | Anticancer agent comprising a yatapoxvirus mutant and uses thereof |
US8470327B2 (en) | 2009-05-11 | 2013-06-25 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof |
CA2825861A1 (en) * | 2010-01-26 | 2011-08-04 | Robert S. Hodges | Conjugates utilizing platform technology for stimulating immune response |
CA2838999C (en) | 2011-07-14 | 2021-02-16 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses |
-
2013
- 2013-03-14 US US13/828,988 patent/US9649375B2/en active Active
-
2014
- 2014-03-12 AR ARP140100906A patent/AR095367A1/es unknown
- 2014-03-13 MX MX2015012399A patent/MX2015012399A/es unknown
- 2014-03-13 TW TW107137751A patent/TW201925238A/zh unknown
- 2014-03-13 TW TW103109171A patent/TWI654205B/zh not_active IP Right Cessation
- 2014-03-13 AU AU2014244071A patent/AU2014244071B2/en not_active Ceased
- 2014-03-13 JP JP2016502011A patent/JP2016519061A/ja active Pending
- 2014-03-13 CA CA2906519A patent/CA2906519A1/en not_active Abandoned
- 2014-03-13 EP EP14776544.0A patent/EP2970386A4/en not_active Withdrawn
- 2014-03-13 CN CN201480028403.5A patent/CN105377876A/zh active Pending
- 2014-03-13 EA EA201591747A patent/EA030004B1/ru not_active IP Right Cessation
- 2014-03-13 WO PCT/US2014/025968 patent/WO2014160171A2/en active Application Filing
-
2016
- 2016-08-31 HK HK16110325.7A patent/HK1222184A1/zh unknown
-
2017
- 2017-05-10 US US15/591,386 patent/US10137194B2/en active Active - Reinstated
-
2018
- 2018-10-04 AU AU2018241125A patent/AU2018241125A1/en not_active Abandoned
- 2018-10-31 US US16/176,743 patent/US10537634B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
TW201925238A (zh) | 2019-07-01 |
US9649375B2 (en) | 2017-05-16 |
EA030004B1 (ru) | 2018-06-29 |
EP2970386A2 (en) | 2016-01-20 |
US10137194B2 (en) | 2018-11-27 |
AR095367A1 (es) | 2015-10-14 |
WO2014160171A3 (en) | 2015-04-23 |
US10537634B2 (en) | 2020-01-21 |
AU2014244071B2 (en) | 2018-07-05 |
WO2014160171A2 (en) | 2014-10-02 |
EP2970386A4 (en) | 2016-10-26 |
AU2014244071A1 (en) | 2015-10-29 |
TW201514208A (zh) | 2015-04-16 |
CN105377876A (zh) | 2016-03-02 |
MX2015012399A (es) | 2016-03-03 |
AU2018241125A1 (en) | 2018-10-25 |
TWI654205B (zh) | 2019-03-21 |
HK1222184A1 (zh) | 2017-06-23 |
US20190054168A1 (en) | 2019-02-21 |
JP2016519061A (ja) | 2016-06-30 |
US20170258902A1 (en) | 2017-09-14 |
US20140271650A1 (en) | 2014-09-18 |
CA2906519A1 (en) | 2014-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2563646T3 (es) | Composiciones y métodos relacionados con variantes de la proteína A (SpA) | |
EA201791086A1 (ru) | Человеческие антитела против гемагглютинина вируса гриппа | |
EA201391170A1 (ru) | Терапевтическое средство на основе дрожжей для лечения хронического гепатита b | |
EA201890729A1 (ru) | Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками | |
BR112016025009A2 (pt) | anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície | |
EA201791675A1 (ru) | Человеческие антитела к гликопротеину вируса эбола | |
CL2018000226A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
PH12021550822A1 (en) | Compositions and methods for the treatment of viral infections | |
EA201591771A1 (ru) | Человеческие антитела к белку f респираторного синцитиального вируса и способы их применения | |
EA201891415A8 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
BR112018013407A2 (pt) | anticorpos e conjugados dos mesmos | |
EA202191622A1 (ru) | Стабилизированные растворимые f-белки rsv до слияния | |
EA201390856A1 (ru) | Инактивация вирусов с применением улучшенного способа растворитель-детергент | |
CL2008002092A1 (es) | Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas. | |
EA201300867A1 (ru) | ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ | |
ES2682981T3 (es) | Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas | |
BR112017009790A2 (pt) | anticorpos direcionados ao anti-ang2 e métodos de uso | |
EA201692279A1 (ru) | Способ уменьшения иммуногенности белка и пептида | |
EA201892233A1 (ru) | Композиции и способы, связанные с иммуногенами вич-1 | |
WO2012047267A3 (en) | Polyvalent immunogen | |
EA202090084A1 (ru) | Новый терапевтический ферментный слитый белок и его применение | |
EA201591747A1 (ru) | Иммуногенный пептидный конъюгат и способ индуцирования терапевтического гуморального ответа против вируса гриппа с его применением | |
EA201792269A1 (ru) | Полипептиды, нацеленные на слияние вич | |
EA201890187A1 (ru) | Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита | |
WO2017053525A3 (en) | Influenza vaccine and therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |